comparemela.com

Page 8 - Ableson Tyrosine News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023

BOSTON and ATLANTA, March 23, 2023 /PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (

United statesMiltonh wernerAlex loboInhibikase therapeutics incInhibikase or companySternir incCompany contactInhibikase therapeuticsAbelson tyrosine kinasesAbelson tyrosine kinaseAbleson tyrosineMultiple system atrophy

Inhibikase Therapeutics to Report Fourth Quarter and Full-Year 2022 Financial Results on March 31, 2023

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.

United statesAlex loboMiltonh wernerInhibikase therapeutics incInhibikase or companySternir incCompany contactInhibikase therapeuticsAbelson tyrosine kinasesAbelson tyrosine kinaseAbleson tyrosineMultiple system atrophy

Inhibikase Therapeutics to Present at the International Conference on Alzheimer s and Parkinson s Diseases and related neurological disorders

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.

United statesVastra gotalands lanMiltonh wernerAlex loboMilton wernerCompany phaseInhibikase therapeutics incCompany contactInternational conference on alzheimerDrug developmentExchange commissionInhibikase or companySternir incInhibikase therapeuticsAbelson tyrosine kinasesChief executive officer

Inhibikase Therapeutics to Host Virtual R&D Event on March 22, 2023

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.

United statesMiltonh wernerAlex loboInhibikase therapeutics incCompany contactExchange commissionInhibikase or companySternir incInhibikase therapeuticsAbelson tyrosine kinasesMultiple system atrophyChronic myelogenousAbelson tyrosine kinaseAbleson tyrosinePrivate securities litigation reform actHealth care amp hospitals

Inhibikase Therapeutics Provides Interim Update on the 501 Bioequivalence Study of IkT-001Pro

/PRNewswire/ Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing protein kinase.

United statesMiltonh wernerAlex loboMilton wernerInhibikase therapeutics incCompany contactExchange commissionInhibikase or companySternir incInhibikase therapeuticsAbelson tyrosine kinasesChronic myelogenous leukemiaChief executiveAbelson tyrosine kinaseOrphan drug designationAbleson tyrosine

vimarsana © 2020. All Rights Reserved.